ndra_8k
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of
1934
|
Date of
Report (Date of earliest event reported)
|
August
17, 2020
|
ENDRA Life Sciences Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-37969
|
|
26-0579295
|
|
(State
or other jurisdiction of incorporation
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
3600
Green Court, Suite 350 Ann Arbor, MI
|
|
48105
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
|
|
|
|
Registrant's
telephone number, including area code
|
|
(734)
335-0468
|
|
|
|
|
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common
stock, par value $0.0001 per share
|
NDRA
|
The
Nasdaq Stock Market LLC
|
|
Warrants,
each to purchase one share of Common Stock
|
NDRAW
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☑
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02
Results
of Operations and Financial Condition
On
August 17, 2020, ENDRA Life Sciences Inc. issued a press release
announcing its financial results for the quarter and year ended
June 30, 2020. A copy of the press release is being furnished as
Exhibit 99.1 to this Current Report on Form 8-K.
The
information in Item 2.02 of this Current Report on Form 8-K and
Exhibit 99.1 attached hereto is intended to be furnished and shall
not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or
otherwise subject to the liabilities of that section, nor shall it
be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly set
forth by specific reference in such filing.
Item
9.01
Financial
Statements and Exhibits.
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
|
Press
Release dated August 17, 2020, furnished herewith.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
ENDRA Life Sciences Inc.
|
|
August
17, 2020
|
|
|
|
By:
|
/s/
Francois Michelon
|
|
|
Name:
|
Francois
Michelon
|
|
|
Title:
|
President
and Chief Executive Officer
|